Stage FocusSeries A, Series B+
GeographyChina, US
TypeVC
Last Activity2024
Industry Focus
Industries
BiotechMedTechSynthetic Biology
Technical BenchStrong
Investor TypeDeepTech Specialist
ExposureMostly DeepTech Investments
Bio
Lilly Asia Ventures is a biomedical venture capital firm. Fund VII closed at its $700M hard cap in 2024, with total AUM exceeding $1.2B across 6 funds. Fund VI was $1.35B ($900M core plus $450M opportunity vehicle). The firm was originally associated with Eli Lilly but now operates as an independent biomedical specialist.
The tri-geography model covers Shanghai (China HQ), Hong Kong (Asia hub), a...
Similar Funds
Ally Bridge Group
New York, United States
DeepTech NativeBiotechMedTechSeries ASeries B+
LYFE Capital
Singapore, Singapore
DeepTech NativeBiotechMedTechSeries ASeries B+
Sherpa Healthcare Partners
Shanghai, China
DeepTech NativeBiotechMedTechSynthetic BiologySeries ASeries B+
Vivo Capital
Palo Alto, United States
DeepTech NativeBiotechMedTechSeedSeries A
5AM Ventures
Boston, United States
DeepTech NativeBiotechMedTechSeries ASeries B+
Abingworth
London, United Kingdom
DeepTech NativeBiotechMedTechSeedSeries A